Psychedelic Therapy
Follow the rapidly evolving world of psychedelic medicine. From FDA approval pathways and clinical trials to state legalization and cutting-edge brain research — a weekly digest for anyone tracking the psychedelic therapy revolution.
Subscribe to receive new issues
Recent Issues
One dose rewired their brains a month later
Psilocybin Causes Lasting White Matter Changes in Drug-Naive Adults A Nature Communications study (UCSF/Imperial College London; n=28 ent
7 new psychedelic bills passed in one month
New Trial Data: Chronic Suicidal Ideation and Cocaine Use Disorder An open-label JCP pilot (n=20)(https://www.psychiatrist.com/jcp/efficacy-safety-single-dose-psilocybin-chronic-suicidal-id
One psilocybin dose alters brain structure
FDA Leadership Disruption Clouds Late-2026 Approval Window FDA Commissioner Makary resigned; acting Commissioner Kyle Diamantas — a lawyer with no scientific background — has taken over wit
VA just gave MDMA to veterans. It's official.
VA Launches First MDMA Trial; Ibogaine Sourcing Named Next Bottleneck The VA launched an RCT of MDMA-assisted therapy(https://news.va.gov/press-room/va-launches-mdma-assisted-mental-health-th
Psychedelics could be FDA-approved this summer
Trump EO Signed; FDA Issues Three Priority Vouchers and First Ibogaine Derivative IND Trump signed Executive Order 14237 ("Accelerating Medical Treatments for Serious Mental Illness") on Ap
Trump's ibogaine order changes everything
Federal Policy: Trump Expected to Sign Ibogaine Research Executive Order Trump is expected to sign an executive order directing federal agencies to advance ibogaine research for veterans' P
Psychedelics at a Tipping Point: Phase 3 Wins, Big Pharma Bets & State Laws Move
Phase 2 and 3 Trial Results A double-blind RCT of inhaled 5-MeO-DMT (GH001)(https://bbrfoundation.org/content/inhalable-formulation-psychedelic-drug-rapidly-helped-patients-treatment-resistan
More from Oria
Is AI replacing humans on job markets?
With surging AI investments and automation capabilities, is the job market facing mass displacement or new opportunities? We analyze AI's dual impact on headcount, exploring the paradox of job destruction versus creation.
Agentic software development
AI is rapidly transforming the software development lifecycle. This newsletter tracks emerging agentic tools and frameworks, providing enterprise-focused coverage on code generation, governance, deployment, and security from leading tech players and startups.
AppSec Briefing
A briefing on application security developments — supply chain attacks, AI code risks, DevSecOps tooling, and how engineering teams are securing their software pipelines.
SRE Briefing
A briefing on site reliability engineering — production incidents, observability developments, AIOps, SLO practices, and how teams are keeping systems reliable.
CI/CD & Release Engineering Briefing
A briefing on CI/CD and release engineering — pipeline tooling, deployment strategies, build optimization, and developer productivity metrics for engineers who own the path from commit to production.
Platform and Infra Briefing
A briefing on platform and infrastructure engineering — Kubernetes, cloud infrastructure, networking, infrastructure as code, and the cloud native ecosystem.
Longevity & Anti-Aging Science
Track the latest breakthroughs in aging research, clinical trials, and longevity science. From age reversal trials and peptide therapies (BPC-157, rapamycin) to stem cell research and NMN studies — curated weekly for people serious about living longer and healthier.
Biohacking Therapies & Devices
Your weekly guide to the tools, therapies, and devices biohackers actually use. Covering red light therapy, cold plunge and sauna science, wearables (Oura, WHOOP, Ultrahuman), and the latest health tracking technology — backed by research, not hype.